BR112012008983A2 - "formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol." - Google Patents

"formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol."

Info

Publication number
BR112012008983A2
BR112012008983A2 BR112012008983A BR112012008983A BR112012008983A2 BR 112012008983 A2 BR112012008983 A2 BR 112012008983A2 BR 112012008983 A BR112012008983 A BR 112012008983A BR 112012008983 A BR112012008983 A BR 112012008983A BR 112012008983 A2 BR112012008983 A2 BR 112012008983A2
Authority
BR
Brazil
Prior art keywords
medical formulation
suspension medical
enhancing
stability
pharmaceutical composition
Prior art date
Application number
BR112012008983A
Other languages
English (en)
Portuguese (pt)
Inventor
Lise-Marie Fueg
Rudi Mueller-Walz
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012008983(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of BR112012008983A2 publication Critical patent/BR112012008983A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012008983A 2009-10-16 2010-10-15 "formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol." BR112012008983A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918149.6A GB0918149D0 (en) 2009-10-16 2009-10-16 Improved medicinal aerosol formulation
PCT/EP2010/065573 WO2011045432A1 (en) 2009-10-16 2010-10-15 Improved medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
BR112012008983A2 true BR112012008983A2 (pt) 2016-04-05

Family

ID=41462450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008983A BR112012008983A2 (pt) 2009-10-16 2010-10-15 "formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol."

Country Status (26)

Country Link
US (3) US20120282189A1 (enExample)
EP (3) EP4327807A3 (enExample)
JP (6) JP2013507430A (enExample)
CN (1) CN102665675B (enExample)
AU (1) AU2010305698C9 (enExample)
BR (1) BR112012008983A2 (enExample)
CA (1) CA2776359C (enExample)
CL (1) CL2012000947A1 (enExample)
CY (1) CY1116109T1 (enExample)
DK (2) DK2881108T3 (enExample)
ES (2) ES2533372T3 (enExample)
FI (1) FI2881108T3 (enExample)
GB (1) GB0918149D0 (enExample)
HR (2) HRP20150174T1 (enExample)
HU (1) HUE065583T2 (enExample)
IL (1) IL219161B (enExample)
LT (1) LT2881108T (enExample)
MX (1) MX2012004337A (enExample)
NZ (1) NZ599901A (enExample)
PL (2) PL2488158T3 (enExample)
PT (2) PT2881108T (enExample)
RS (2) RS53883B1 (enExample)
SI (2) SI2881108T1 (enExample)
SM (2) SMT202400119T1 (enExample)
WO (1) WO2011045432A1 (enExample)
ZA (1) ZA201202452B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
FR2420972A1 (fr) 1978-03-31 1979-10-26 Roussel Uclaf Application du peroxyde de thenoyle a titre de medicament
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
DE2914181C2 (de) 1979-04-07 1982-06-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie
JPS6135815A (ja) 1984-07-28 1986-02-20 Sanshin Seisakusho:Kk 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
ES2216800T3 (es) * 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
DE4321288A1 (de) 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
EP0731688B1 (en) 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
AU718263B2 (en) 1995-04-14 2000-04-13 Smithkline Beecham Corporation Metered dose inhaler for salmeterol
JP3707107B2 (ja) 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
CA2279648C (en) 1997-01-30 2007-04-24 Alpenstock Holdings Limited Haemostatic aerosol composition
AU718967B2 (en) 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
CA2338680C (en) 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
HU226164B1 (en) 1998-11-13 2008-05-28 Jagotec Ag Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HRP20021025B1 (hr) 2000-05-22 2013-11-22 Chiesi Farmaceutici S.P.A. Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom
WO2002007672A2 (en) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
US20020076382A1 (en) 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
ATE320242T1 (de) 2000-10-09 2006-04-15 3M Innovative Properties Co Medizinische aerosolzusammensetzung
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TWI324934B (en) 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
LT3494995T (lt) 2002-03-01 2020-04-10 Chiesi Farmaceutici S.P.A. Ypatingai smulki formoterolio kompozicija
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US20060193610A1 (en) 2003-07-12 2006-08-31 Jong-Hun Han Aromatic emitting apparatus for using cigarjack
MXPA06003100A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis de liberacion retardada.
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0918150D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
JP2015036045A (ja) * 2013-08-12 2015-02-23 株式会社泉技研 骨質改善のための超音波音響システム及び超音波音響機器の作動方法

Also Published As

Publication number Publication date
JP2015129162A (ja) 2015-07-16
CN102665675B (zh) 2014-03-19
EP4327807A2 (en) 2024-02-28
IL219161A0 (en) 2012-06-28
US20140314684A1 (en) 2014-10-23
US20170189423A1 (en) 2017-07-06
LT2881108T (lt) 2024-04-10
RS65391B1 (sr) 2024-04-30
SI2488158T1 (sl) 2015-04-30
HRP20240402T1 (hr) 2024-06-07
NZ599901A (en) 2013-08-30
PL2488158T3 (pl) 2015-06-30
PT2881108T (pt) 2024-03-13
PT2488158E (pt) 2015-03-16
JP2019182878A (ja) 2019-10-24
JP2017057223A (ja) 2017-03-23
HRP20150174T1 (hr) 2015-05-22
PL2881108T3 (pl) 2024-06-17
IL219161B (en) 2019-12-31
CA2776359C (en) 2015-12-08
ES2533372T3 (es) 2015-04-09
JP7203701B2 (ja) 2023-01-13
EP2488158B1 (en) 2014-12-24
HK1211207A1 (en) 2016-05-20
AU2010305698A1 (en) 2012-04-26
US10471077B2 (en) 2019-11-12
AU2010305698C9 (en) 2014-04-17
JP2023026517A (ja) 2023-02-24
JP6568511B2 (ja) 2019-08-28
JP2013507430A (ja) 2013-03-04
CA2776359A1 (en) 2011-04-21
CN102665675A (zh) 2012-09-12
HUE065583T2 (hu) 2024-06-28
SMT202400119T1 (it) 2024-05-14
AU2010305698C1 (en) 2013-07-25
ZA201202452B (en) 2013-09-25
US20120282189A1 (en) 2012-11-08
SI2881108T1 (sl) 2024-04-30
MX2012004337A (es) 2012-08-31
RS53883B1 (sr) 2015-08-31
AU2010305698B2 (en) 2012-12-20
ES2973882T3 (es) 2024-06-24
EP2488158A1 (en) 2012-08-22
EP2881108B1 (en) 2023-12-27
EP2881108A1 (en) 2015-06-10
EP4327807A3 (en) 2024-04-24
FI2881108T3 (fi) 2024-03-13
HK1173077A1 (en) 2013-05-10
JP2025148616A (ja) 2025-10-07
GB0918149D0 (en) 2009-12-02
CY1116109T1 (el) 2017-02-08
WO2011045432A1 (en) 2011-04-21
DK2881108T3 (da) 2024-03-11
SMT201500052B (it) 2015-05-05
CL2012000947A1 (es) 2012-12-14
DK2488158T3 (en) 2015-03-23

Similar Documents

Publication Publication Date Title
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
MX2021009476A (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
DK3962455T3 (en) New pharmaceutical composition for drug delivery
MX2013012975A (es) Composiciones farmaceuticas.
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BRPI0919753B8 (pt) forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
BR112012015337B8 (pt) composição farmacêutica, cartucho de aerossol, método para carregar um cartucho de aerossol, conjunto de componentes e uso de uma composição farmacêutica
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
WO2012016845A3 (en) Pharmaceutical formulation comprising a phosphodiesterase inhibitor
BR112012008983A2 (pt) "formulação medicinal em suspensão, composição farmacêutica, produto, uso de cromolina sódica,e, método para aumentar a estabilidade de uma formulação medicinal em suspensão de aerossol."
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
BR112013006362A2 (pt) uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
ZA202007890B (en) Stable pharmaceutical compositions for pressurized metered dose inhalers

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]